COMPANY PROFILE

Bio Geometry

Explore full profile

Drugs that deliver, faster and cheaper

ChinaFounded 2022Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Bio Geometry

BioGeometry is an AI-driven pharmaceutical company focused on developing next-generation, programmable protein medicines. The company leverages advanced technologies such as geometric deep learning, structural biology, immunology, and synthetic biology to create innovative treatments for oncology, autoimmune, and infectious diseases. BioGeometry aims to address the high costs, long lead times, and low success rates associated with traditional macromolecular therapeutics by utilizing artificial intelligence to design medicines. The company serves clients in the pharmaceutical and biotechnology sectors, offering solutions that expedite drug development processes and reduce costs. BioGeometry's business model revolves around the digitalization and automation of drug discovery, which allows for faster and more efficient development cycles. Revenue is generated through partnerships, licensing agreements, and the commercialization of proprietary medicines.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: China
Employees: 10
Open positions: None listed
Dealroom signal: 80.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Technology: Artificial Intelligence
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Bio Geometry.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Jun 2026	$28M	$110M	Gaorong Ventures · Fortune Venture · Lianxing Capital	↗
SEED✓Equity / VC	Jun 2024	—	—	Gaorong Ventures · ShengJing360 · Z.ai \| Zhipu AI · Jiangmen Investment Fund	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Bio Geometry website traffic

Latest recorded traffic for Bio Geometry is 2.3K monthly website visits, up 21.1% over the last three months. Bio Geometry's team declined 9.1% over the past year.

Latest monthly visits2.3K 3-month web change+21.1% 1-year team growth-9.1%

Monthly website visitsJun 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DBDiffuse BioWe're building push-button software for drug design, driven by breakthroughs in generative AI	San Francisco, United States	Operational	11	$125K	$500K
MOMoleculeMindA leading AI protein design platform company	Haidian, China	Operational
ELEarendil LabsAI Solutions to Protein-based Therapeutics	China	Operational
ATApertura Gene TherapyLeverages ML to engineer novel capsids, gene regulatory elements to simultaneously enhance gene therapies	New York City, United States	Operational
MTMatwings TechnologyLeveraging its independently developed general AI for protein design, AccelProtein	Minhang District, China	Operational
ATAukera TherapeuticsBiotech company that develops novel therapeutics for patients suffering from mTOR protein related diseases	Basel, Switzerland	Operational
ABAtavistik BioPrecision allosteric therapeutics for oncology and rare diseases.	Cambridge, United States	Operational
ABAperiam BioTaking the guesswork out of biotechnology with computer vision that illuminates critical parts of protein chemistry	New York City, United States	Operational